Faecalibacterium prausnitzii

Structure & Biochemistry

Taxonomy	Domain Bacteria → Phylum Firmicutes → Class Clostridia → Order Eubacteriales → Family Ruminococcaceae → Faecalibacterium prausnitzii (single species; two phylogroups, A and B)
Cell morphology	Short rod, 2–5 µm × 0.5–1 µm; Gram-positive (but outer membrane-like outer layer); non-motile; non-spore-forming; single polar flagellum-like structure in some strains; extreme obligate anaerobe
Oxygen sensitivity	Half-life in air <1 minute at room temperature; dies rapidly on exposure to even trace O₂; survives longer in mucus (glutathione-rich environment); requires strict anoxic handling for culture — major barrier to clinical translation
Butyrate production pathway	Ferments acetate + dietary fibre → butyryl-CoA → butyrate via butyrate kinase (BuK) pathway (distinct from phosphotransbutyrylase pathway used by Clostridium); acetate cross-feeding from Bifidobacterium and Akkermansia is essential co-substrate
MAMs (Microbial Anti-inflammatory Molecules)	Low-MW secreted peptides/metabolites; partially characterised; inhibit IKK phosphorylation of IκBα → prevent NF-κB nuclear translocation → suppress IL-8, IL-6, IL-1β in colonocytes and macrophages; active in cell-free supernatant fractions
Genome	~2.9 Mb (ATCC 27766); ~2,800 ORFs; relatively streamlined; rich in carbohydrate transport and fermentation genes; GC content ~57%
Cultivation challenges	Not included in standard stool culture panels; requires strictly anaerobic conditions (Hungate technique or anaerobic cabinet); doubling time ~2–3h under optimal conditions; sensitive to antibiotics, PPIs, and dietary change

Mechanisms of Benefit

• Butyrate → colonocyte energy & barrier function Butyrate is the primary fuel for colonic epithelial cells (colonocytes) — providing ~70% of their energy via β-oxidation. Adequate butyrate supply maintains colonocyte viability, tight junction protein expression (claudin-1, occludin, ZO-1), mucus secretion (MUC2), and the physiological hypoxic gradient that protects anaerobic commensals. Butyrate depletion = colonocyte energy deficiency = barrier breakdown = bacterial translocation = inflammation.
• MAMs → NF-κB inhibition → anti-inflammatory cytokines F. prausnitzii secretes MAMs that penetrate colonocytes and block IKKβ activation, preventing IκBα phosphorylation and NF-κB p65 nuclear translocation. In vitro, F. prausnitzii supernatant reduces IL-8 secretion from TNF-α-stimulated colonocytes by ~70%. In DSS colitis mouse models, oral administration of F. prausnitzii or cell-free supernatant prevents and treats colitis comparably to anti-TNF therapy in some models.
• Butyrate as epigenetic regulator — HDAC inhibition Butyrate is a potent histone deacetylase (HDAC) inhibitor; at physiological concentrations (1–5 mM) in colonocytes, it alters gene expression by increasing histone acetylation. Effects include: induction of Foxp3 in naive T cells → Tregs; suppression of pro-inflammatory gene transcription in macrophages; induction of Reg3γ antimicrobial peptides; inhibition of colonocyte cell cycle at G1 (pro-differentiation, anti-tumorigenic).
• Cross-feeding ecology — syntrophic relationship F. prausnitzii cannot synthesise butyrate from glucose alone in the colon; it requires acetate as a co-substrate from cross-feeding bacteria (Bifidobacterium longum, Akkermansia muciniphila, Blautia obeum). Acetate → butyryl-CoA conversion drives efficient butyrate output. Disruption of cross-feeding (by antibiotics, diet change, or Bifidobacterium loss) directly depletes F. prausnitzii even without direct antimicrobial effect.
• Association with Treg balance and mucosal tolerance F. prausnitzii-conditioned medium induces IL-10 production from peripheral blood mononuclear cells and macrophages; promotes CD103+ tolerogenic DCs in the lamina propria; indirectly induces Foxp3+ Tregs via butyrate (HDAC inhibition). This Treg-promoting activity contributes to mucosal tolerance and anti-inflammatory homeostasis in the healthy colon.

Microbiome Context

Clinical Associations

Condition	Association	Evidence	Status
Crohn's Disease	Depleted 4–8× in active CD vs healthy; depletion predicts post-surgical recurrence; lower abundance at diagnosis → worse 2-year outcome	Multiple cohorts	Strongly depleted
Ulcerative Colitis	Reduced in active UC; FMT from F. prausnitzii-rich donors correlates with higher remission rates; restoration correlates with mucosal healing	Cohort + FMT	Depleted in active disease
Type 2 Diabetes / Obesity	Reduced abundance; inversely correlates with inflammatory cytokines, HbA1c; fibre interventions restore both F. prausnitzii and glycaemic control	Observational + interventional	Inverse correlation
Colorectal Cancer	Reduced in CRC tissue vs normal mucosa; potentially protective via butyrate-mediated anti-proliferative effects; insufficient evidence for causality	Observational	Inverse (tentative)
Healthy aging	Abundance declines with age; low-F. prausnitzii microbiomes associate with frailty and inflammation (inflammaging); dietary fibre intake is primary modulator	Cross-sectional studies	Declines with age

Research & Therapeutic Status

• Live biotherapeutic candidate — technical challenges Multiple biotech companies developing F. prausnitzii as a live biotherapeutic product (LBP) for IBD. Key challenges: extreme O₂ sensitivity requires microencapsulation (alginate, starch-based, or pH-responsive coatings) for oral delivery; manufacturing at scale requires anaerobic GMP facilities; shelf-life at standard refrigeration is poor. Phase 1 safety trials underway (2023–2025) for enteric-coated formulations.
• Dietary fibre as F. prausnitzii modulator Inulin, arabinoxylan, pectin, and resistant starch are preferred substrates or cross-feeding substrates. Clinical trials (FIBERS, EcologiX) show dietary fibre interventions increase F. prausnitzii 2–5×; correlating with reduced CRP, improved gut barrier markers (FABP2), and patient-reported symptom improvement in IBS/IBD patients.
• F. prausnitzii as FMT quality indicator High F. prausnitzii donor abundance correlates with FMT engraftment success and clinical outcomes in UC trials. Proposed as a quality/efficacy marker for FMT donor stool selection; low-F. prausnitzii donors may need supplementation or pairing with fibre-rich diets.

Cross-Atlas Connections

References

• Sokol H et al. (2008). Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105(43):16731–6.
• Quévrain E et al. (2016). Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. Gut 65(3):415–25.
• Louis P, Flint HJ (2009). Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 294(1):1–8.
• Machiels K et al. (2014). A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63(8):1275–83.
• Miquel S et al. (2013). Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol 16(3):255–61.